Jimma University Laboratory of Drug Quality (JuLaDQ)

Introduction

Jimma University (JU) is a public higher educational institution established in December 1999 by the amalgamation of Jimma College of Agriculture (founded in 1952), and Jimma Institute of Health Sciences (established in 1983).

JU is engaged in research, training and community services. It is laying the ground work for the development of pharmaceutical industry through conducting pharmaceutical research and training of pharmaceutical professionals in the country.

Jimma University Laboratory of Drug Quality (JuLaDQ) was established in 2009/10 as part of IUC-JU collaborative research program between Jimma University and consortium of Flemish Universities from Belgium and became operational since 2011. The establishment began in collaboration with Laboratory of Drug Quality and Registration (DruQuaR) of Ghent University, 9000-Ghent, Belgium by applying QbD principles, and now contributing to quality control (QC) analytics of medicines in the Horn of Africa.
Currently JuLaDQ is one of the core labs in Jimma University that is being engaged in research and provision of pharmaceutical quality testing service using the conventional dichotomous approach (the Pharmacopoeial monograph-based conform/non-conform methods), and the analytical quality-by-design (aQbD) risk-based desirability function approach on essential medicines with particular emphasis on antimicrobials medicines used for infectious diseases: neglected tropical diseases/soil-transmitted helminthiasis (STH), malaria, tuberculosis (TB) and HIV/AIDS.
JuLaDQ has a well-established quality system based on quality management guidelines of WHO Prequalification scheme and the ISO/IEC 17025 2017 quality requirements where the processes of prequalification and accreditation are on good progress.

Vision

  • The vision of JuLaDQ to become center of excellence and recognized as a global leader in pharmaceutical analytical research, training and services.

Mission

  • To promote and advance pharmaceutical research, training, and services that can contribute to improved access to quality medicines; national and global initiatives of countering the problem of Substandard and Falsified (SF) medicines; and national regulatory maturity with new and existing medicines by innovating, discovering, developing and transferring new products/knowledge/procedures/services/tools/technologies.

Strategic objectives

  • To support human resource development in pharmaceutical sciences and beyond.
  • To support efficient and effective pharmaceutical regulatory systems in the country and beyond.
  • To provide a GLP/GMP compliant accredited pharmaceutical analytical facility for research, training and service in pharmaceutical quality assurance and control and other related regulatory activities.
  • To provide an independent laboratory for analysis and quality control of human and veterinary pharmaceutical, biotechnological, and complementary medicines.
  • To provide the required support to pre-clinical and clinical development of potential new medicines and drug delivery systems

Organogram

                               

“Professor Sultan Suleman, Founder and Director for JuLaDQ

                    After a symposium on Quality pharmaceutical Drugs: from order to patient.